Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-08-02
2011-08-02
Saeed, Kamal (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S305000
Reexamination Certificate
active
07989500
ABSTRACT:
The present invention provides novel cycloalkylmethylamine analogs, and methods of preparing cycloalkylmethylamine analogs. The present invention also provides methods of using cycloalkylmethylamine analogs and compositions of cycloalkylmethylamine analogs. The pharmaceutical compositions of the compounds of the present invention can be advantageously used for treating and/or preventing obesity and obesity related co-morbid indications.
REFERENCES:
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4929629 (1990-05-01), Jeffery
patent: 5112598 (1992-05-01), Biesalski
patent: 5556611 (1996-09-01), Biesalski
patent: 5596019 (1997-01-01), Mattson
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 6610887 (2003-08-01), Senanayake et al.
patent: WO 98/11884 (1998-03-01), None
patent: WO 98/13034 (1998-04-01), None
patent: WO 00/32178 (2000-06-01), None
patent: WO 01/00187 (2001-01-01), None
patent: WO 01/00205 (2001-01-01), None
patent: WO 01/51453 (2001-07-01), None
patent: WO 02/36540 (2002-05-01), None
patent: WO 02/060424 (2002-08-01), None
patent: WO 02/083631 (2002-10-01), None
patent: WO 2004/058237 (2004-07-01), None
patent: WO 2004/096202 (2004-11-01), None
PCT International Search Report and Written Opinion, PCT Application No. PCT/US07/78682, Jul. 3, 2008, 7 pages.
Bamba, M. et al., “Release Mechanisms in Gelforming Sustained Release Preparations,” International Journal of Pharmaceutics, 1979, pp. 307-315, vol. 2.
Butler, D.E. et al., “Facile Cycloalkylation of Arylacetonitriles in Dimethyl Sulfoxide,” The Journal of Organic Chemistry, May-Aug. 1971, pp. 1308-1309, vol. 36, No. 9.
Cheng, Y-C. et al., “Relationship Between the Inhibition Constant (K1) and the Concentration of Inhibitor Which Causes 50 Per Cent Inhibition (I50) of an Enzymatic Reaction,” Biochemical Pharmacology, 1973, pp. 3099-3108, vol. 22.
Crespi, C.L., “Higher-Throughput Screening with Human Cytochromes P450,” Current Opinion in Drug Discovery & Development, 1999, pp. 15-19, vol. 2, No. 1.
During, M.J. et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,” Annals of Neurolology, Apr. 1989, pp. 351-356, vol. 25, No. 4.
Favreau, L.V. et al., “Improved Reliability of the Rapid Microtiter Plate Assay Using Recombinant Enzyme in Predicting CYP2D6 Inhibition in Human Liver Microsomes,” Drug Metabolism and Disposition, 1989, pp. 436-439, vol. 27, No. 4.
Fioravanzo, E. et al., “General and Independent Approaches to Predict HERG Affinity Values,” Internet Electronic Journal of Molecular Design, Sep. 2005,pp. 625-646, vol. 4, No. 9.
Glick, S.D. et al., “Enantioselective Behavioral Effects of Sibutramine Metabolites,” European Journal of Pharmacology, 2000, pp. 93-102, vol. 397.
Goodson, J.M. “Dental Applications,” Medical Applications of Controlled Release, Langer and Wise (eds.), Wiley, New York, 1984, pp. 115-138.
Houston, J.B., “Utility of In Vitro Drug Metabolism Data in Predicting In Vivo Metabolic Clearance,” Biochemical Pharmacology, 1994, pp. 1467-1469, vol. 47, No. 9.
Howard, M.A. et al., “Intracerebral Drug Delivery in Rats with Lesion-Induced Memory Deficits,” J. Neurosurg., 1989, pp. 105-112, vol. 71.
Jeffery, J.E. et al., “Synthesis of Sibutramine, a Novel Cyclobutylalkylamine Useful in the Treatment of Obesity, and Its Major Human Metabolites,” Journal of the Chemical Society, Perkin Transactions 1, Sep. 7, 1996, pp. 2079-2216, No. 17.
Korzekwa, K.R. et al., “Evaluation of Atypical Cytochrome P450 Kintecs with Two-Substrate Models: Evidence That Multiple Substrates Can Simultaneously Bind to Cytochrome P450 Active Sites,” Biochemistry, 1998, pp. 4137-4147, vol. 37.
Langer, R., “New Methods of Drug Delivery,” Science, Sep. 28, 1990, pp. 1527-1533, vol. 249.
Langer, R. et al., “Chemical and Physical Structure of Polymers as Carriers for Controlled Release of Bioactive Agents: A Review,” 1983, Journal of Macromolecular Science: Reviews in Macromolecular Chemistry and Physics, 1983, pp. 61-126, vol. 23, No. 1.
Levy, R. et al., “Inhibition of Calcification of Bioprosthetic Heart Valves by Local Controlled-Release Diphosphonate,” Science, Apr. 12, 1985, pp. 190-192, vol. 228, No. 4696.
Maiti, G. et al., “A Mild and Efficient Method for the Selective Cleavage of tert-Butyldimethylsilyl Ethers to Alcohols,” Tetrahedron Letters, 1997, pp. 495-498, vol. 38, No. 3.
New Zealand Examination Report, New Zealand Application No. 576214, Aug. 5, 2010, 2 pages.
Roden, D. M. et al. “Genetics of Acquired Long QT Syndrome,” The Journal of Clinical Investigation, Aug. 2005, pp. 2025-2032, vol. 115, No. 8.
Saudek, C.D. et al., “A Preliminary Trial of the Programmable Implantable Medication System for Insulation Delivery,” The New England Journal of Medicine, Aug. 31, 1989, pp. 574-579, vol. 321, No. 9.
Sefton, M.V., “Implantable Pumps,” Critical Reviews in Biomedical Engineering, 1987, pp. 201-240, vol. 14, Issue 3.
Verma, R.K. et al., “Osmotically Controlled Oral Drug Delivery,” Drug Development and Industrial Pharmacy, 2000, pp. 695-708, vol. 26, No. 7.
Zhou, J. et al., “Novel Potent Human Ether-à-Go-Go-Related Gene (hERG) Potassium Channel Enhancers and Their in Vitro Antiarrhythmic Activity,” Molecular Pharmacology, 2005, pp. 876-884, vol. 68, No. 3.
Chinese First Office Action, Chinese Application No. 200780042355.5, Nov. 4, 2010, 12 pages.
Bhat Laxminarayan
Bhat Seema Rani
Fenwick & West LLP
Reviva Pharmaceuticals, Inc.
Saeed Kamal
LandOfFree
Synthesis, methods of using, and compositions of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synthesis, methods of using, and compositions of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synthesis, methods of using, and compositions of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2783402